Funding agencies: This work was supported by NIH grants NS59910 and NS65851 and the California Tobacco Related Disease Research Program 17RT-0119.
Article first published online: 12 JUN 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 8, pages 947–957, July 2012
How to Cite
Quik, M., Perez, X. A. and Bordia, T. (2012), Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord., 27: 947–957. doi: 10.1002/mds.25028
Relevant conflicts of interest/financial disclosures: Maryka Quik is on a patent for the use of nicotine for L-dopa-induced dyskinesias.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 17 JUL 2012
- Article first published online: 12 JUN 2012
- Manuscript Accepted: 8 APR 2012
- Manuscript Revised: 13 MAR 2012
- Manuscript Received: 9 FEB 2012
- nigrostriatal damage;
- Parkinson's disease
Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson's disease. This idea initially stemmed from the results of epidemiological studies that demonstrated that smoking is associated with a decreased incidence of Parkinson's disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes containing nAChRs, including α4β2, α6β2, and/or α7, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine's ability to reduce/halt the neuronal damage that arises in Parkinson's disease. In addition to a potential neuroprotective action, nicotine also has antidepressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease. © 2012 Movement Disorder Society